All In Biotech

Drug Trial Radar · NCT01818752

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Aug 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 955 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

955

Actual

Start

Jul 8, 2013

Primary completion

Jul 15, 2016

Study completion Nov 4, 2016

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).

Conditions

  • Multiple Myeloma

Interventions

  • CarfilzomibDrug

    Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.

  • BortezomibDrug

    Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.

  • MelphalanDrug

    Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.

  • PrednisoneDrug

    Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.

Locations

213 sites in 30 countries. Site status is shown where the registry gives one.

  • California Cancer Associates for Research & Excellence, Inc. (cCARE)

    Fresno, California

  • Marin Cancer Care

    Greenbrae, California

  • Sutter Gould Medical Foundation

    Modesto, California

  • Innovative Clinical Research Institute

    Whittier, California

  • UF Health Shands Cancer Hospital

    Gainesville, Florida

  • Evanston KelIogg Cancer Center

    Evanston, Illinois

  • Billings Clinic Cancer Center

    Billings, Montana

  • Maimonides Cancer Center

    Brooklyn, New York

  • Weill Cornell Medical Center

    New York, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • Saint Francis Health System

    Greenville, South Carolina

  • Spartanburg Regional Healthcare System

    Spartanburg, South Carolina

  • Santee Hematology Oncology

    Sumter, South Carolina

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Centro de educacion medica c investigacioncs clinicas "Norberto Quimo' (CEMIC)

    Buenos Aires, Argentina

  • Sanatorio Britanico S.A.

    Santa Fe, Argentina

  • Royal North Shore Hospital, Haematology Department

    New South Wales, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • St. Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Central Coast Local Health District

    North Gosford, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Eastern Health - Box Hill Hospital

    Box Hill, Victoria, Australia

  • St. Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Border Medical Oncology

    Wodonga, Victoria, Australia

  • Medical University of Innsbruck, University Clinic for Internal Medicine V

    Innsbruck, Austria

  • Elisabeth Linz Hospital

    Linz, Austria

  • Vienna Wilhelminen Hospital

    Vienna, Austria

  • CHR de La Citadelle (ENG: Citadelle Regional Hospital Center)

    Liège, Belgium

  • CHU Mont-Godinne

    Yvoir, Belgium

  • ZNA, Stuivenberg

    Antwerp, Antwerpen, Belgium

  • Saint Joseph Clinic Arlon, Department of Hematology

    Arlon, Luxembourg, Belgium

  • University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv, Hematology Clinic

    Plovdiv, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv, Oncology and Hematology Clinic

    Plovdiv, Bulgaria

  • Military Medical Academy - Multiprofile Hospital for Active Treatment, Sofia, Hematology and Oncology Clinic

    Sofia, Bulgaria

  • Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Hematology Clinic

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment "Sveta Marina", Varna

    Varna, Bulgaria

  • CSSS-Champlain-Charles LeMoyne

    Greenfield Park, Quebec, Canada

  • 307 Hospital of PLA

    Beijing, China

Showing 40 of 213 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.